Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2017-05-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD007941.pub3PMID 28541603PMCID PMC6481581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

  2017cited by this paper
• Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

  2016cited by this paper
• Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

  2016cited by this paper
• Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

  2016cited by this paper
• ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial.

  2014cited by this paper
• Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.

  2013cited by this paper
• Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.

  2013cited by this paper
• Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial

  2012cited by this paper
• Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

  2012cited by this paper
• Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.

  2012cited by this paper
• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

  2012cited by this paper
• Persistent socioeconomic inequalities in cancer survival in the United States: 1973-2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin's lymphoma.

  2012cited by this paper
• A 10‐year experience with treatment of high and standard risk Hodgkin disease: Six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved

  2012cited by this paper
• ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

  2012cited by this paper
• Chapter 10: Addressing reporting biases

  2011cited by this paper
• ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

  2011cited by this paper
• Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.

  2011cited by this paper
• Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

  2010cited by this paper
• Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

  2010cited by this paper
• Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.

  2009cited by this paper
• Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

  2009cited by this paper
• The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

  2009cited by this paper
• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.

  2008cited by this paper
• Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy.

  2008cited by this paper
• Chapter 9: Analysing Data and Undertaking Meta-Analyses

  2008cited by this paper
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

  2008cited by this paper
• Phase 3 trials suggest ways to improve current hematologic cancer therapies.

  2008cited by this paper
• Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

  2008cited by this paper
• Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin’s Lymphoma: Final Results of the GHSG HD7 Trial

  2008cited by this paper
• Chapter 16: Special Topics in Statistics

  2008cited by this paper
• Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): A randomized trial of the Michelangelo, GITIL and IIL cooperative groups

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Searching for Studies

  2008cited by this paper
• Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.

  2007cited by this paper
• A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: Results of a phase II study of the Groupe d'Études des Lymphomes de l'Adulte (GELA)

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• OP31 10-year results of the HD9 trial of the German Hodgkin Study Group comparing baseline and escalated BEACOPP chemotherapy for advanced Hodgkin lymphoma

  2007cited by this paper
• Is BEACOPP better than ABVD?

  2007influential reference
• Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

  2007cited by this paper
• Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.

  2007cited by this paper
• Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

  2007cited by this paper
• Ten-year results of a German Hodgkin Study Group randomized trial of standard and increased dose BEACOPP chemotherapy for advanced Hodgkin lymphoma (HD9)

  2007cited by this paper
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Long-Term Follow-Up of BEACOPPescalated Chemotherapy in Patients with Advanced-Stage Hodgkin Lymphoma on Behalf of the German Hodgkin Study Group.

  2007cited by this paper
• First-line treatment of Hodgkin’s lymphoma

  2006cited by this paper
• Lymphome de Hodgkin (LH): avancées et perspectives récentes

  2006cited by this paper
• Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma

  2006cited by this paper
• Evaluation of Acute and Early Cardiotoxicity in Survivors of Hodgkin's Disease Treated with ABVD or BEACOPP Regimens

  2006cited by this paper
• The EORTC strategy in the treatment of Hodgkin's lymphoma

  2005cited by this paper
• ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

  2005cited by this paper
• Clinical trials in North America

  2005influential reference
• A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

  2005cited by this paper
• State-of-the-art therapeutics: Hodgkin's lymphoma.

  2005cited by this paper
• Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group.

  2005cited by this paper
• An international approach to the treatment of Hodgkin's disease in the elderly: launch of the SHIELD study programme

  2005cited by this paper
• Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.

  2005cited by this paper
• What Is New in Lymphoma?

  2004influential reference
• Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.

  2004cited by this paper
• Beacopp Chemotherapy for Advanced Hodgkin’s Disease: Results of Further Analyses of the HD9- and HD12- Trials of the German Hodgkin Study Group (GHSG).

  2004cited by this paper
• Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co‐operative Oncology Group Study

  2003cited by this paper
• Hodgkin's disease--clinical trials and travails.

  2003cited by this paper
• Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma

  2003cited by this paper
• Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

  2003cited by this paper
• Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease.

  2003cited by this paper
• Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

  2003cited by this paper
• Chemotherapy for Hodgkin's disease.

  2003cited by this paper
• Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.

  2003cited by this paper
• Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte.

  2002cited by this paper
• Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design and rationale.

  2002cited by this paper
• New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.

  2002cited by this paper
• Epidemiology and etiology of Hodgkin's lymphoma.

  2002cited by this paper
• Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP.

  2002cited by this paper
• Current clinical trials for the treatment of adult advanced‐stage Hodgkin's disease: GELA experiences

  2002cited by this paper
• Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.

  2002cited by this paper
• Hodgkin's lymphoma: basing the treatment on the evidence.

  2001cited by this paper
• Modelling of chemotherapy: The effective dose approach

  2001cited by this paper
• Hodgkin's disease.

  2000cited by this paper
• [Treatment of Hodgkin's disease using the German Study Group protocol. Personal experience and results].

  2000cited by this paper
• Primärtherapie des Morbus Hodgkin

  2000cited by this paper
• Greater curability in advanced Hodgkin's disease?

  1999cited by this paper
• Greater curability in advanced Hodgkin's disease?

  1999cited by this paper
• Current chemotherapeutic possibilities in pancreaticobiliary cancer.

  1999cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

  1998cited by this paper
• Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

  1998cited by this paper
• Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease

  1998cited by this paper
• The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission.

  1998cited by this paper
• Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

  1998cited by this paper
• Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.

  1997cited by this paper
• BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group.

  1997cited by this paper
• Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group.

  1996cited by this paper
• [Hodgkin's disease].

  1996cited by this paper
• Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

  1992cited by this paper
• The Published Data

  1990cited by this paper
• Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

  1989cited by this paper
• Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.

  1987cited by this paper
• Cancer: Principles and Practice of Oncology

  1983cited by this paper
• Report of the Committee on Hodgkin's Disease Staging Classification.

  1971cited by this paper

• Real‐World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR)

  2025cites this paper
• Comparative Numerical Analyses of Heat Generation in Pristine and Encapsulated Metallic Nanostructures for Enhanced Hyperthermia Efficiency

  2025cites this paper
• Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

  2025cites this paper
• Viral oncogenesis in cancer: from mechanisms to therapeutics

  2025cites this paper
• The Effect of Chemotherapy Treatment on Cognitive Impairment and Clinical Symptoms in Hodgkin Lymphoma Patients

  2025cites this paper
• Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.

  2025cites this paper
• Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism.

  2025cites this paper
• Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)

  2024influential citation
• Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience

  2024cites this paper
• How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

  2024cites this paper
• Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting

  2023influential citation
• Immunotherapy for Hodgkin lymphoma: from monoclonal antibodies to chimeric antigen receptor T-cell therapy.

  2023cites this paper
• Classic Hodgkin Lymphoma in Adolescents and Young Adults.

  2023cites this paper
• Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.

  2023cites this paper
• Cubosome: A Potential Nanocarrier in Cancer Therapy

  2023cites this paper
• Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study

  2023cites this paper
• Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study

  2023cites this paper
• Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin’s Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study

  2023cites this paper
• Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy

  2022cites this paper
• Investigating early progression of Hodgkin lymphoma in a two-center analysis.

  2022cites this paper
• The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma

  2022cites this paper
• The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma.

  2022cites this paper
• Acute Myeloid Leukemias After the Treatment of Classical Hodgkin’s Lymphoma: A Literature Review

  2022cites this paper
• Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma

  2022cites this paper
• Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

  2022cites this paper
• Nomogram model and risk score predicting overall survival and guiding clinical decision in patients with Hodgkin’s lymphoma: an observational study using SEER population-based data

  2022cites this paper
• Das Hodgkin-Lymphom in fortgeschrittenen Stadien

  2022influential citation
• Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients

  2022cites this paper
• Die Wahl der Chemotherapie unter einer PET-CT-geführten Therapiedeeskalation hat einen signifikanten Einfluss auf die Fertilität und Lebensqualität junger Hodgkin-Patientinnen und Patienten

  2022cites this paper
• First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes

  2022cites this paper
• Advances of podophyllotoxin and its derivatives: patterns and mechanisms.

  2022cites this paper
• Development, Therapeutic Evaluation and Theranostic Applications of Cubosomes on Cancers: An Updated Review

  2022influential citation
• Metal nanoparticles as a promising technology in targeted cancer treatment

  2022cites this paper
• First Extensive Analysis of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis

  2022cites this paper
• Comparative evaluation of the effectiveness of primary treatment regimens in patients with classical Hodgkin’s lymphoma from the group of unfavorable prognosis

  2021cites this paper
• AYA Considerations for Aggressive Lymphomas

  2021cites this paper
• Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients

  2021cites this paper
• ОПЫТ ЛЕЧЕНИЯ ЛИМФОМЫ ХОДЖКИНА РЕФРАКТЕРНОГО ТЕЧЕНИЯ

  2021cites this paper
• Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism

  2021cites this paper
• Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

  2021cites this paper
• Is classical Hodgkin lymphoma a different disease in the elderly? A single-center retrospective cohort study.

  2021cites this paper
• Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)

  2021cites this paper
• Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

  2021cites this paper
• Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

  2021cites this paper
• Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

  2021cites this paper
• Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.

  2021cites this paper
• Linfomas en la era COVID-19

  2021cites this paper
• How I treat advanced Hodgkin lymphoma — a global view

  2020cites this paper
• How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

  2020cites this paper
• An update on disease biomarkers for Hodgkin lymphoma

  2020cites this paper
• Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.

  2020cites this paper
• RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

  2020cites this paper
• Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.

  2020cites this paper
• ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma

  2020cites this paper
• Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review

  2020cites this paper
• Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma.

  2020cites this paper
• Current advances in Hodgkin’s lymphoma

  2019influential citation
• Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma

  2019cites this paper
• Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma - A Real-world Analysis.

  2019cites this paper
• Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study.

  2019influential citation
• Circulating biomarkers in classical Hodgkin lymphoma

  2019cites this paper
• Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

  2019cites this paper
• Hodgkin’s Lymphoma: Analysis Results of Volgograd Regional Registry

  2019cites this paper
• Fertility Preservation in Women with Hematological Malignancies

  2019cites this paper
• Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements

  2019cites this paper
• Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

  2019cites this paper
• Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.

  2019cites this paper
• FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?

  2019cites this paper
• A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer

  2018cites this paper
• Treatment of advanced stage classical Hodgkin lymphoma: a pathway through the maze

  2018cites this paper
• Current considerations in AYA Hodgkin lymphoma

  2018cites this paper
• Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

  2018cites this paper
• Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome

  2018influential citation
• Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice.

  2018cites this paper
• Hodgkin lymphoma: A review and update on recent progress

  2018cites this paper
• Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

  2018cites this paper
• 18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma

  2018cites this paper
• Hodgkin Lymphoma in Adults.

  2018cites this paper
• The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma

  2018cites this paper
• Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma

  2018cites this paper
• How does escalated BEACOPP chemotherapy compare with ABVD in people with early unfavorable or advanced stage Hodgkin lymphoma

  2017cites this paper
• Hodgkin's lymphoma in developing countries: can we go further?

  2017cites this paper
• Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study

  2017cites this paper
• Treatment of advanced-stage Hodgkin lymphoma.

  2016cites this paper